Abstract
GIST is a rare tumor, but determining its incidence is a challenge. Incidence from prior reports ranges from 0.43 to 2.2 per 100,000, but the reports that examined stomach specimen from autopsy or surgery of other diseases suggest that there may be occult GISTs. The distinction between benign and malignant cases is also ambiguous. Cancer registries may not be a reliable source because many limit the reportability of the tumor into only malignant cases. An analysis using hospital-based cancer registries in Japan suggests that overtly malignant cases are about one third of cases that are considered as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
DeMatteo RP, Maki R, Agulnik M, et al. Gastrointestinal stromal tumor. In: AJCC cancer staging manual. Chicago: Springer; 2017.
Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.
Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37:1527–35.
Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31:113–20.
Global Cancer Observatory. 2012. https://gco.iarc.fr/. Accessed 1 May 2018.
Estimate of Bariatric Surgery Numbers, 2011-2016. 2018. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers. Accessed 1 May 2018.
SEER. Program coding and staging manual 2016. 2016. https://seer.cancer.gov/manuals/2016/SPCSM_2016_maindoc.pdf. Accessed 1 May 2018.
Rubin BP, Fletcher JA, Fletcher CD. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Surg Pathol. 2000;8:5–10.
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.
Miettinen MM, Lasota J, Coless CL, et al. Gastrointestinal stromal tumours. In: WHO classification of tumours of the digestive system. 4th ed. Geneva: World Health Organization; 2010.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.
Higashi T, Nakamura F, Shibata A, Emori Y, Nishimoto H. The national database of hospital-based cancer registries: a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan. Jpn J Clin Oncol. 2014;44:2–8.
Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009;23:15–34, vii.
Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011;108:314–8.
Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889–94.
Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32:210–8.
Lopes LF, West RB, Bacchi LM, van de Rijn M, Bacchi CE. DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): Comparison between 2 different antibodies. Appl Immunohistochem Mol Morphol. 2010;18:333–7.
West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107–13.
Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202:623–9.
Chiang NJ, Chen LT, Tsai CR, Chang JS. The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: a nation-wide cancer registry-based study. BMC Cancer. 2014;14:102.
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.
Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72.
Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–74.
Yanagimoto Y, Takahashi T, Muguruma K, et al. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer. 2015;18:426–33.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Higashi, T. (2019). Epidemiology. In: Kurokawa, Y., Komatsu, Y. (eds) Gastrointestinal Stromal Tumor. Springer, Singapore. https://doi.org/10.1007/978-981-13-3206-7_1
Download citation
DOI: https://doi.org/10.1007/978-981-13-3206-7_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-3205-0
Online ISBN: 978-981-13-3206-7
eBook Packages: MedicineMedicine (R0)